|
|
|
Insider
Information: |
Nelsen Robert |
Relationship: |
10% Owner |
City: |
Chicago |
State: |
IL |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
34 |
|
Direct
Shares |
34,315,145 |
|
Indirect Shares
|
122,760,866 |
|
|
Direct
Value |
$483,958,248 |
|
|
Indirect Value
|
$1,018,468,749 |
|
|
Total
Shares |
157,076,011 |
|
|
Total
Value |
$1,502,426,997 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
17
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
17
|
0
|
|
|
|
Gain/Loss Ratio : |
-17.0
|
0.0
|
Percentage
Gain/Loss : |
-17.5%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Adolor Corp |
ADLR |
Director |
2007-05-17 |
1,207,523 |
2003-12-08 |
402,874 |
Premium* |
|
Illumina Inc |
ILMN |
Director |
2004-02-03 |
11,423 |
2004-02-03 |
2,915,298 |
Premium* |
|
Alnylam Pharmaceuticals Inc |
ALNY |
10% Owner |
|
0 |
2004-05-27 |
222,500 |
Premium* |
|
Cyclacel Pharmaceuticals Inc |
CYCC |
Director, 10% Owner |
2004-03-19 |
0 |
2004-03-19 |
2,054,271 |
Premium* |
|
Neurogesx Inc |
NGSX |
Director, 10% Owner |
2011-07-21 |
4,187,777 |
2011-07-26 |
4,187,777 |
Premium* |
|
Trubion Pharmaceuticals, Inc |
TRBN |
10% Owner |
2010-10-28 |
0 |
2010-10-28 |
0 |
Premium* |
|
Kythera Biopharmaceuticals Inc |
KYTH |
Former Director |
2015-03-24 |
10,295 |
2015-03-13 |
947,309 |
Premium* |
|
Receptos, Inc. |
RCPT |
10% Owner |
2014-05-14 |
2,058,634 |
|
0 |
Premium* |
|
Bluebird Bio, Inc. |
BLUE |
10% Owner |
2013-06-24 |
1,793,588 |
2013-06-24 |
0 |
Premium* |
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2017-02-28 |
109,230 |
2017-02-28 |
40,599 |
Premium* |
|
Fate Therapeutics Inc |
FATE |
Director, 10% Owner |
2013-10-04 |
0 |
2013-10-04 |
2,473,188 |
Premium* |
|
Achaogen Inc |
AKAO |
10% Owner |
2014-03-17 |
1,418,657 |
2014-03-17 |
0 |
Premium* |
|
Sage Therapeutics, Inc. |
SAGE |
Director |
2015-11-09 |
107,950 |
2015-11-09 |
1,124,699 |
Premium* |
|
VBI Vaccines Inc |
VBIV |
10% Owner |
2015-08-17 |
3,397,830 |
|
0 |
Premium* |
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2018-03-05 |
0 |
2018-03-05 |
0 |
Premium* |
|
Bellerophon Therapeutics Inc |
BLPH |
Director, 10% Owner |
|
0 |
2015-02-19 |
965,660 |
Premium* |
|
Pulmatrix Inc |
PULM |
Former 10% owner |
2015-06-15 |
0 |
2018-04-03 |
3,436,456 |
Premium* |
|
Adesto Technologies Corp |
IOTS |
10% Owner |
2015-10-30 |
2,276,511 |
2015-10-26 |
0 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
10% Owner |
2019-07-17 |
4,242,051 |
2016-07-06 |
4,637,137 |
Premium* |
|
Impinj Inc |
PI |
10% Owner |
2016-07-26 |
1,366,735 |
2016-07-26 |
0 |
Premium* |
|
Sienna Biopharmaceuticals, Inc. |
SNNA |
10% Owner |
2017-08-01 |
0 |
2019-02-22 |
1,865,800 |
Premium* |
|
Q32 Bio Inc |
QTTB |
10% Owner |
2019-05-21 |
5,768,694 |
2018-04-02 |
6,068,695 |
Premium* |
|
Denali Therapeutics Inc. |
DNLI |
Director |
2021-06-02 |
12,432 |
2021-06-02 |
9,668,749 |
Premium* |
|
Quanterix Corp |
QTRX |
10% Owner |
2020-11-24 |
1,889 |
2020-11-24 |
1,214,770 |
Premium* |
|
Unity Biotechnology Inc |
UBX |
Director, 10% Owner |
2018-05-07 |
0 |
2018-05-07 |
1,682,417 |
Premium* |
|
Twist Bioscience Corp |
TWST |
10% Owner |
2018-11-02 |
0 |
2018-11-02 |
954,146 |
Premium* |
|
Karuna Therapeutics, Inc. |
KRTX |
Director, 10% Owner |
2021-04-13 |
5,269 |
2021-04-13 |
1,456,435 |
Premium* |
|
Vir Biotechnology, Inc. |
VIR |
Director |
2024-05-30 |
584,148 |
2024-05-30 |
12,950,556 |
Premium* |
|
Beam Therapeutics Inc. |
BEAM |
10% Owner |
2021-06-30 |
28,111 |
2021-06-30 |
2,921,519 |
Premium* |
|
908 Devices Inc. |
MASS |
10% Owner |
2020-12-22 |
5,725,045 |
2020-12-22 |
0 |
Premium* |
|
Sana Biotechnology, Inc. |
SANA |
Director, 10% Owner |
2024-02-08 |
1,353 |
2024-02-08 |
22,759,772 |
Premium* |
|
Lyell Immunopharma, Inc. |
LYEL |
Director, 10% Owner |
2021-06-21 |
0 |
2021-06-21 |
18,206,358 |
Premium* |
|
Prime Medicine, Inc. |
PRME |
Director, 10% Owner |
2022-10-24 |
0 |
2024-02-15 |
15,472,674 |
Premium* |
|
Neumora Therapeutics, Inc. |
NMRA |
10% Owner |
2023-09-22 |
0 |
2023-11-14 |
4,131,207 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
239 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 9 of 10
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-09 |
4 |
B |
$10.53 |
$327,262 |
I/I |
31,079 |
4,078,922 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-08 |
4 |
B |
$10.78 |
$1,017,821 |
I/I |
92,251 |
4,047,843 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-09-25 |
4 |
B |
$10.80 |
$681,464 |
I/I |
60,740 |
3,724,883 |
1.5 |
% |
|
NGSX |
Neurogesx Inc |
Director |
|
2007-05-02 |
4 |
B |
$11.00 |
$2,497,000 |
I/I |
227,000 |
227,000 |
2.25 |
- |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-09-22 |
4 |
B |
$11.14 |
$445,600 |
I/I |
40,000 |
3,664,143 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-10 |
4 |
B |
$11.37 |
$198,481 |
I/I |
17,275 |
4,096,197 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-03 |
4 |
B |
$11.38 |
$255,140 |
I/I |
22,420 |
3,882,318 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-07 |
4 |
B |
$11.50 |
$347,208 |
I/I |
30,192 |
3,955,592 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-06 |
4 |
B |
$11.55 |
$497,597 |
I/I |
43,082 |
3,925,400 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-09-26 |
4 |
B |
$11.73 |
$398,820 |
I/I |
34,000 |
3,758,883 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-13 |
4 |
B |
$11.75 |
$371,923 |
I/I |
31,653 |
4,127,850 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-11-14 |
4 |
B |
$11.98 |
$40,217 |
I/I |
3,357 |
4,131,207 |
1.5 |
% |
|
BLPH |
Bellerophon Therapeutics ... |
Director |
|
2015-02-19 |
4 |
B |
$12.00 |
$2,551,992 |
I/I |
212,666 |
965,660 |
2.25 |
- |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-09-27 |
4 |
B |
$12.31 |
$301,644 |
I/I |
24,504 |
3,783,387 |
1.5 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
4,637,137 |
2.25 |
- |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-09-28 |
4 |
B |
$13.06 |
$563,699 |
I/I |
41,951 |
3,825,338 |
1.5 |
% |
|
NMRA |
Neumora Therapeutics, Inc... |
10% Owner |
|
2023-09-29 |
4 |
B |
$13.98 |
$483,149 |
I/I |
34,560 |
3,859,898 |
1.5 |
% |
|
RCPT |
Receptos, Inc. |
10% Owner |
|
2013-05-14 |
4 |
B |
$14.00 |
$3,982,790 |
D/D |
284,485 |
2,101,376 |
2.45 |
- |
|
PI |
Impinj Inc |
10% Owner |
|
2016-07-26 |
4/A |
D |
$14.00 |
$298,382 |
D/D |
(21,313) |
1,366,735 |
0 |
- |
|
PI |
Impinj Inc |
10% Owner |
|
2016-07-26 |
4 |
D |
$14.00 |
$372,974 |
D/D |
(26,641) |
1,361,408 |
0 |
- |
|
TWST |
Twist Bioscience Corp |
10% Owner |
|
2018-11-02 |
4 |
B |
$14.00 |
$1,050,000 |
I/I |
75,000 |
954,146 |
1.5 |
- |
|
QTRX |
Quanterix Corp |
10% Owner |
|
2017-12-11 |
4 |
B |
$15.00 |
$3,990,000 |
D/D |
266,000 |
1,537,684 |
2.45 |
- |
|
KYTH |
Kythera Biopharmaceutical... |
Former Director |
|
2015-03-24 |
4 |
OE |
$16.00 |
$108,256 |
D/D |
5,987 |
10,295 |
0 |
- |
|
KRTX |
Karuna Therapeutics, Inc. |
Director |
|
2019-07-02 |
4 |
B |
$16.00 |
$3,200,000 |
I/I |
200,000 |
1,681,435 |
2.25 |
- |
|
PRME |
Prime Medicine, Inc. |
Director |
|
2022-10-24 |
4 |
B |
$17.00 |
$13,600,000 |
I/I |
800,000 |
6,128,297 |
2.25 |
% |
|
239 Records found
|
|
Page 9 of 10 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|